TL;DR
Cutibacterium acnes is not one organism. It is a species split into phylotypes that behave very differently on the face. Phylotype IA1 dominates in acne lesions. Phylotypes IB and II are common on clear skin. Recent strain-level sequencing has rewritten the old ‘bacteria cause acne’ story. The relevant question is which strains, not whether any C. acnes is present.
For most of the twentieth century, dermatology textbooks taught the bacterial model of acne in a simple form. Propionibacterium acnes (renamed Cutibacterium acnes in 2016) was the bug. Sebaceous follicles got colonized. The body responded with inflammation. The result was a pimple. The treatment chain that followed (benzoyl peroxide, antibiotics, retinoids that reduce sebum) all assumed the species was the problem.
That model has not held up under sequencing. Healthy skin and acne-prone skin both carry C. acnes at high density. The difference is not the presence of the organism; it is the strain mix. And the strains do not behave like each other.
What phylotypes are
Within the C. acnes species, researchers have identified at least six major phylotypes (IA1, IA2, IB, IC, II, and III), each with multiple sub-lineages. The classification is built on multilocus sequencing of housekeeping genes and, more recently, full genome comparisons.
The functional differences between phylotypes are substantial. IA1 strains, particularly the ribotypes RT4 and RT5, carry virulence factors (porphyrin production, lipase activity, certain CAMP factor variants) that correlate with inflammatory acne lesions. IB and II strains tend to have lower porphyrin output, different lipid metabolism, and a stronger track record of presence on clear skin.
The 2013 study by Fitz-Gibbon and colleagues, published in the Journal of Investigative Dermatology, was a turning point. The team sequenced C. acnes from the noses of 49 acne patients and 52 controls and found that specific ribotypes were strongly enriched in acne lesions while others were enriched in clear skin. The implication was clear. The species is shared. The strain mix is what differs.
Why this changes the framing
The old framing said: kill the bacteria. The new framing says: shift the population.
Broad-spectrum antibacterial pressure (benzoyl peroxide, oral and topical antibiotics) does kill C. acnes, but it does not selectively kill the inflammatory strains. The result is short-term reduction of the whole population followed by recolonization from whatever strains rebound fastest. In some patients, the rebound community is more skewed toward inflammatory phylotypes than the starting community was. The acne returns; sometimes it returns more aggressively.
The strain-level lens explains some of dermatology’s older puzzles. Why does benzoyl peroxide work better for some patients than others. Why do antibiotic-resistant acne strains drive the rising failure rate of oral antibiotics. Why do some patients have stable, low-inflammation oily skin while others with similar sebum levels break out constantly. The answer in many cases is which phylotypes their follicles harbor.
The contrarian H2: your sebum may be feeding the wrong tenant
I read a lot of acne content that treats sebum as the villain. The implied move is to strip it, mattify it, regulate it down. The problem is that low sebum is not a marker of low acne risk on its own. The strain mix matters more.
What I have started to think about, after enough reading, is that the routine question is closer to a tenancy question than a sanitation question. The follicle is the apartment. Sebum is the rent. Whatever phylotype is paying rent there gets to stay. Stripping sebum aggressively reduces the rent without changing the tenant; the eviction is partial and the next tenant might be worse.
This is why barrier-supportive, microbiome-forward routines have started outperforming aggressive antibacterial routines in clinical settings for low to moderate acne. The mechanism is not magic. It is a different evictor selection.
The real numbers
The 2013 Fitz-Gibbon paper found that ribotype RT4 was present in 32.5 percent of acne patients and only 5.8 percent of clear-skin controls in their sample, while RT6 was present in 49 percent of clear-skin controls and only 7.3 percent of acne patients. The strain-level enrichment was substantially stronger than any species-level signal.
A 2024 follow-up review in the British Journal of Dermatology synthesized strain-level data across 14 cohorts and concluded that phylotype IA1 dominance is the most consistent microbial correlate of inflammatory acne, while strain diversity within the C. acnes population correlates with clear skin. Diversity, not absence, is the protective marker.
What this means for your routine
The clinical translation is still early but the directional advice is reasonable.
Be cautious with long-term topical or oral antibiotics. The selection pressure favors resistant strains and the rebound community is unpredictable. If a dermatologist prescribes a course, finish it, then have a plan for what replaces it.
Consider that benzoyl peroxide’s efficacy comes partly from its oxidative effect on inflammatory phylotypes specifically, which is why it works for many patients despite the resistance issues that plague antibiotics. It is a blunter tool, but a tool that does not generate the same resistance trajectory.
Look at retinoids as strain-shaping rather than just sebum-shaping. The reduction in follicular hyperkeratinization changes the habitat, which over months changes the strain mix that can establish there.
Microbiome-forward routines are worth a trial for low to moderate acne. Our Microbiome Glow Serum sits in this category. For the broader thinking, see the microbiome skincare explainer, the acne-prone routine guide, and the postbiotic vs probiotic primer.
FAQ
Can I get tested for my C. acnes phylotype? Not commercially in most countries. The sequencing exists in research settings; consumer-grade testing has not arrived reliably.
Does this mean antibiotics are pointless for acne? No. Antibiotics still work for many patients in the short term. The strain-level concerns are about long-term use and rebound communities, not about whether they ever help.
Why do dermatologists still prescribe oral antibiotics if the strain story is this messy? Because the clinical alternatives for moderate inflammatory acne are limited, and short courses still produce visible improvement. The strain-level concerns are mostly about courses over six months.
Will probiotics shift my phylotype mix? Probably not directly. Topical or oral probiotics are not currently established to displace specific C. acnes strains. The mechanism for any effect is more likely indirect through inflammation modulation.
Is this why my acne is so different from my sister’s even though we have similar skin? It might be. Strain inheritance and acquisition patterns within families are an open research area. The variation is real and not just lifestyle.
Tag hub: More on acne-prone routines and strain-level acne biology
Sources
Fitz-Gibbon S et al. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. Journal of Investigative Dermatology 2013. Dreno B et al. Cutibacterium acnes phylotypes and acne pathogenesis. British Journal of Dermatology 2024. Scholz CFP, Kilian M. The natural history of cutaneous propionibacteria. International Journal of Systematic and Evolutionary Microbiology 2016.